<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1466" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1466/" /><meta name="ncbi_pagename" content="Myotonic Dystrophy Type 2 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Myotonic Dystrophy Type 2 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Myotonic Dystrophy Type 2" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/07/03" /><meta name="citation_author" content="Joline C Dalton" /><meta name="citation_author" content="Laura PW Ranum" /><meta name="citation_author" content="John W Day" /><meta name="citation_pmid" content="20301639" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1466/" /><meta name="citation_keywords" content="Proximal Myotonic Myopathy (PROMM)" /><meta name="citation_keywords" content="Proximal Myotonic Myopathy (PROMM)" /><meta name="citation_keywords" content="Cellular nucleic acid-binding protein" /><meta name="citation_keywords" content="CNBP" /><meta name="citation_keywords" content="Myotonic Dystrophy Type 2" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Myotonic Dystrophy Type 2" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Joline C Dalton" /><meta name="DC.Contributor" content="Laura PW Ranum" /><meta name="DC.Contributor" content="John W Day" /><meta name="DC.Date" content="2013/07/03" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1466/" /><meta name="description" content="Myotonic dystrophy type 2 (DM2) is characterized by myotonia (90% of affected individuals) and muscle dysfunction (weakness, pain, and stiffness) (82%), and less commonly by cardiac conduction defects, iridescent posterior subcapsular cataracts, insulin-insensitive type 2 diabetes mellitus, and testicular failure. Although myotonia (involuntary muscle contraction with delayed relaxation) has been reported during the first decade, onset is typically in the third decade, most commonly with fluctuating or episodic muscle pain that can be debilitating and weakness of the neck flexors and finger flexors. Subsequently, weakness occurs in the elbow extensors and the hip flexors and extensors. Facial weakness and weakness of the ankle dorsiflexors are less common. Myotonia rarely causes severe symptoms." /><meta name="og:title" content="Myotonic Dystrophy Type 2" /><meta name="og:type" content="book" /><meta name="og:description" content="Myotonic dystrophy type 2 (DM2) is characterized by myotonia (90% of affected individuals) and muscle dysfunction (weakness, pain, and stiffness) (82%), and less commonly by cardiac conduction defects, iridescent posterior subcapsular cataracts, insulin-insensitive type 2 diabetes mellitus, and testicular failure. Although myotonia (involuntary muscle contraction with delayed relaxation) has been reported during the first decade, onset is typically in the third decade, most commonly with fluctuating or episodic muscle pain that can be debilitating and weakness of the neck flexors and finger flexors. Subsequently, weakness occurs in the elbow extensors and the hip flexors and extensors. Facial weakness and weakness of the ankle dorsiflexors are less common. Myotonia rarely causes severe symptoms." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1466/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/myotonic-d2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1466/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8992CFE0410DE10000000003590179.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1466_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1466_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/myotonic-d/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/norrie/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1466_"><span class="title" itemprop="name">Myotonic Dystrophy Type 2</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Proximal Myotonic Myopathy (PROMM)</div><p class="contrib-group"><span itemprop="author">Joline C Dalton</span>, MS, <span itemprop="author">Laura PW Ranum</span>, PhD, and <span itemprop="author">John W Day</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1466_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1466_ai__"><div class="contrib half_rhythm"><span itemprop="author">Joline C Dalton</span>, MS<div class="affiliation small">Department of Genetics, Cell Biology, and Development<br />Institute of Human Genetics<br />Genetic Counselor, Paul and Sheila Wellstone Muscular Dystrophy Center<br />University of Minnesota<br />Minneapolis, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nmu@notladcj" class="oemail">ude.nmu@notladcj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Laura PW Ranum</span>, PhD<div class="affiliation small">Director, Center for NeuroGenetics<br />Professor, Department of Molecular Genetics &#x00026; Microbiology<br />University of Florida<br />Gainesville, Florida<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.lfu@munar" class="oemail">ude.lfu@munar</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John W Day</span>, MD, PhD<div class="affiliation small">Director, Neuromuscular Division and Clinics<br />Department of Neurology<br />Stanford University<br />Stanford, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.drofnatS@dwj" class="oemail">ude.drofnatS@dwj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 21, 2006</span>; Last Update: <span itemprop="dateModified">July 3, 2013</span>.</p><p><em>Estimated reading time: 32 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="myotonic-d2.Summary" itemprop="description"><h2 id="_myotonic-d2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Myotonic dystrophy type 2 (DM2) is characterized by myotonia (90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) and muscle dysfunction (weakness, pain, and stiffness) (82%), and less commonly by cardiac conduction defects, iridescent posterior subcapsular cataracts, insulin-insensitive type 2 diabetes mellitus, and testicular failure. Although myotonia (involuntary muscle contraction with delayed relaxation) has been reported during the first decade, onset is typically in the third decade, most commonly with fluctuating or episodic muscle pain that can be debilitating and weakness of the neck flexors and finger flexors. Subsequently, weakness occurs in the elbow extensors and the hip flexors and extensors. Facial weakness and weakness of the ankle dorsiflexors are less common. Myotonia rarely causes severe symptoms.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p><i>CNBP</i> (<i>ZNF9</i>) is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause myotonic dystrophy type 2. <i>CNBP</i> <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 contains a complex repeat motif, (TG)<sub>n</sub>(TCTG)<sub>n</sub>(CCTG)<sub>n</sub>. Expansion of the CCTG repeat causes DM2. The number of CCTG repeats in expanded alleles ranges from approximately 75 to more than 11,000, with a mean of approximately 5,000 repeats. The detection rate of a <i>CNBP</i> CCTG expansion is more than 99% with the combination of routine <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>, <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis, and the PCR repeat-primed assay.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Ankle-foot orthoses, wheelchairs, or other assistive devices as needed for weakness; defibrillator placement for those with arrhythmias; removal of cataracts that impair vision; and testosterone replacement therapy for hypogonadism in males. Myotonia rarely requires treatment. Routine physical activity appears to help maintain muscle strength and endurance and to control musculoskeletal pain. Medications used with some success in pain management include mexilitene, gabapentin, nonsteroidal anti-inflammatory drugs (NSAIDS), low-dose thyroid replacement, low-dose steroids (e.g., 5 mg prednisone on alternate days), and tricyclic antidepressants.</p><p><i>Prevention of secondary complications:</i> Anesthetic risk may be increased and therefore assessment of cardiac and respiratory function before and after surgery are recommended. Prompt treatment of hypothyroidism to reduce secondary weakness.</p><p><i>Surveillance:</i> Annual ECG and echocardiogram or possible cardiac MRI to detect/monitor cardiac conduction defects and cardiomyopathy; annual measurement of fasting serum glucose concentration and glycosylated hemoglobin level; and testing of males every few years for evidence of hypogonadism.</p><p><i>Agents/circumstances to avoid:</i> Cholesterol-lowering medications when associated with increased weakness.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Myotonic dystrophy type 2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. To date, all individuals whose biological parents have been evaluated with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> have had one parent with a <i>CNBP</i> expansion; <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants have not been reported. Each child of an individual with a <i>CNBP</i> expansion has a 50% chance of inheriting the expansion. Neither the size of a predominant <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> nor the total number of different detectable expansions in a single sample can predict disease severity, age of onset, or clinical symptoms. Prenatal testing for pregnancies at increased risk is possible if the presence of a <i>CNBP</i> expansion has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</p></div></div><div id="myotonic-d2.Diagnosis"><h2 id="_myotonic-d2_Diagnosis_">Diagnosis</h2><div id="myotonic-d2.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>Myotonic dystrophy type 2 (DM2) should be suspected in individuals with the following:</p><ul><li class="half_rhythm"><div><b>Muscle weakness</b> with early, clinically detectable weakness on manual motor testing of neck flexors and finger flexors, and later, symptomatic weakness often involving hip-girdle muscles in climbing stairs and arising from chairs</div></li><li class="half_rhythm"><div><b>Myotonia</b> (sustained muscle contraction) that can manifest as grip myotonia (the inability to release a tightened fist quickly) occurring as early as the first decade of life, percussion myotonia (sustained contraction after tapping a muscle with a reflex hammer), or electrical myotonia (repetitive spontaneous discharges observed on EMG). The myotonia in individuals with DM2 is not always detectable by EMG [<a class="bk_pop" href="#myotonic-d2.REF.dabby.2011.745">Dabby et al 2011</a>].</div></li><li class="half_rhythm"><div><b>Posterior subcapsular cataracts</b> detectable as nonspecific vacuoles and opacities on direct ophthalmoscopy or as pathognomonic posterior subcapsular red and green iridescent opacities on slit lamp examination</div></li><li class="half_rhythm"><div><b>Cardiac conduction defects or progressive cardiomyopathy,</b> the former diagnosable as atrioventricular or various intraventricular conduction defects on routine ECG and the latter identifiable as a dilated cardiomyopathy on echocardiography</div></li><li class="half_rhythm"><div><b>Hypogammaglobulinemia,</b> defined as low gamma protein fraction on serum protein electrophoresis or low immunoglobulin G or immunoglobulin M content on immunoprotein electrophoresis, which occurs in 75% of adults with myotonic dystrophy types 1 and 2 but has not been associated with any clinical abnormalities</div></li><li class="half_rhythm"><div><b>Insulin insensitivity</b> that can appear clinically as impaired normalization of glucose on a glucose tolerance test despite normal or elevated serum insulin concentrations, and which predisposes to hyperglycemia and diabetes mellitus</div></li><li class="half_rhythm"><div><b>Primary gonadal failure</b> in males, as evidenced by low serum testosterone concentration, elevated serum FSH concentration, oligospermia, and infertility</div></li></ul></div><div id="myotonic-d2.Testing"><h3>Testing</h3><p><b>Muscle biopsy.</b> Muscle pathology includes atrophic fibers, scattered severely atrophic fibers with pyknotic myonuclei, and marked proliferation of fibers with central nuclei [<a class="bk_pop" href="#myotonic-d2.REF.day.1999.19">Day et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>, <a class="bk_pop" href="#myotonic-d2.REF.schoser.2004c.275">Schoser et al 2004c</a>], all of which occur in both <a href="/books/n/gene/myotonic-d/">myotonic dystrophy type 1</a> (DM1) and DM2 and thus cannot be used to distinguish between them:</p><ul><li class="half_rhythm"><div>Type 1 fiber atrophy is a common feature in individuals with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> DM1, distinguishing it from DM2.</div></li><li class="half_rhythm"><div>Preferential type 2 fiber atrophy has been observed in individuals with DM2 [<a class="bk_pop" href="#myotonic-d2.REF.vihola.2003.1854">Vihola et al 2003</a>, <a class="bk_pop" href="#myotonic-d2.REF.schoser.2004c.275">Schoser et al 2004c</a>, <a class="bk_pop" href="#myotonic-d2.REF.pisani.2008.1405">Pisani et al 2008</a>, <a class="bk_pop" href="#myotonic-d2.REF.giagnacovo.2012.699">Giagnacovo et al 2012</a>].</div></li></ul><div id="myotonic-d2.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><div id="myotonic-d2.Gene"><h5>Gene</h5><p><i>CNBP</i> (formerly <i>ZNF9</i>), the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding cellular nucleic acid-binding protein (zinc finger protein 9), is the only gene in which pathogenic variants are known to cause DM2. <i>CNBP</i> <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 contains a complex repeat motif, (TG)<sub>n</sub>(TCTG)<sub>n</sub>(CCTG)<sub>n</sub>. Expansion of the CCTG repeat causes DM2 [<a class="bk_pop" href="#myotonic-d2.REF.liquori.2001.864">Liquori et al 2001</a>].</p></div><div id="myotonic-d2.Allele_Sizes"><h5>Allele Sizes</h5><p><b>Normal alleles.</b> All three repeat tracts (TG, TCTG, and CCTG) are present as a complex motif on all normal and pathogenic alleles; additionally, the CCTG repeat tract in normal alleles typically contains one or more tetranucleotide interruptions (TCTG or GCTG) [<a class="bk_pop" href="#myotonic-d2.REF.liquori.2003.849">Liquori et al 2003</a>] (see <a class="figpopup" href="/books/NBK1466/figure/myotonic-d2.F1/?report=objectonly" target="object" rid-figpopup="figmyotonicd2F1" rid-ob="figobmyotonicd2F1">Figure 1</a>). The overall length of the (TG)n(TCTG)n(CCTG)n complex repeat in normal alleles ranges from 104 to 176 base pairs. Because TG and TCTG repeat tracts are highly polymorphic, <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> sizes determined by methods other than sequencing are reported in overall base-pair length rather than as a definable number of CCTG repeats.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmyotonicd2F1" co-legend-rid="figlgndmyotonicd2F1"><a href="/books/NBK1466/figure/myotonic-d2.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figmyotonicd2F1" rid-ob="figobmyotonicd2F1"><img class="small-thumb" src="/books/NBK1466/bin/myotonic-d2-Image001.gif" src-large="/books/NBK1466/bin/myotonic-d2-Image001.jpg" alt="Figure 1. . Complex repeat at the DM2 locus." /></a><div class="icnblk_cntnt" id="figlgndmyotonicd2F1"><h4 id="myotonic-d2.F1"><a href="/books/NBK1466/figure/myotonic-d2.F1/?report=objectonly" target="object" rid-ob="figobmyotonicd2F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Complex repeat at the DM2 locus. The DM2 repeat tract is a complex repeat comprising TG, TCTG, and CCTG tracts, in this order. Each repeat can vary in length. On normal alleles, the overall length of the CCTG portion ranges from 11 to 26 tetranucleotide <a href="/books/NBK1466/figure/myotonic-d2.F1/?report=objectonly" target="object" rid-ob="figobmyotonicd2F1">(more...)</a></p></div></div><p>Sequence analysis of 24 normal alleles [<a class="bk_pop" href="#myotonic-d2.REF.liquori.2001.864">Liquori et al 2001</a>, <a class="bk_pop" href="#myotonic-d2.REF.liquori.2003.849">Liquori et al 2003</a>] showed that:</p><ul><li class="half_rhythm"><div>The largest number of uninterrupted CCTG repeats was nine (except for a single case discussed below; see <b>Mutable normal alleles</b>).</div></li><li class="half_rhythm"><div>The overall normal CCTG repeat tract, including any GCTC and TCTG interruptions, ranged from 11 to 26 tetranucleotide repeats.</div></li><li class="half_rhythm"><div>In 85% of unaffected individuals, the overall lengths of the complex repeat tract clearly differ on the two alleles and are thus distinct on analysis of <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> amplicons.</div></li></ul><p><b>Mutable normal alleles (also called intermediate or <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> alleles).</b> No <i>CNBP</i> alleles have been reported in the size range of 177-372 bp (equivalent to ~27-74 CCTG repeats); furthermore, whether normal alleles within any particular size range or with any particular sequence characteristics are prone to expand into the pathogenic range remains unclear at this time. The sequence interruptions that are routinely found within the CCTG tracts of normal alleles are not found in sequenced pathogenic CCTG expansions of <i>CNBP</i> alleles. Loss of these interruptions from normal alleles may increase instability and predispose these repeat tracts to expansion in subsequent generations; although this type of instability has been confirmed for other diseases, it has not yet been observed in individuals with DM2. Consistent with this hypothesis, however, is the report of an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in an unaffected individual in whom 20 uninterrupted CCTG repeats were present on a haplotype identical to that found in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#myotonic-d2.REF.liquori.2003.849">Liquori et al 2003</a>]. Although this individual's repeat tract did not expand when transmitted to the next generation, it is possible that the loss of the sequence interruptions may predispose uninterrupted CCTG repeat tracts to expansion in future generations. Because it has not been confirmed that large normal <i>CNBP</i> repeat alleles can expand into the pathogenic range, alleles with 177-372 bp are referred to more accurately as borderline expansions rather than premutations.</p><p><b>Full <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (or abnormal) alleles.</b> In smaller pathogenic alleles that have been sequenced, only the CCTG portion of the complex repeat has been shown to expand. In large expansions, which cannot be sequenced accurately, alleles greater than 372 bp (equivalent to 75 CCTG repeats) appear to be fully penetrant in causing DM2. Pathogenic alleles range in size from 372 bp to more than 44,000 bp (equivalent to ~75-11,000 CCTG repeats), with a mean of approximately 20,000 bp (equivalent to ~5,000 repeats).</p><p>The CCTG repeat tract displays:</p><ul><li class="half_rhythm"><div><b>Somatic instability.</b> CCTG repeat size increases with age. More than 25% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have two or more CCTG expansion sizes detectable in peripheral blood. This somatic heterogeneity of CCTG repeat size makes it difficult to establish a pathogenic threshold; for example, the affected individual with the shortest identified CCTG repeat expansion on one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (~75 CCTG repeats or ~300 bp) also has an allele with a very large CCTG expansion containing more than 11,000 CCTG repeats or 44,000 bp; either or both of the expanded alleles could be pathogenic [<a class="bk_pop" href="#myotonic-d2.REF.liquori.2001.864">Liquori et al 2001</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>].</div></li><li class="half_rhythm"><div><b>Intergenerational instability.</b> On transmission to the next generation, <i>CNBP</i> repeat length sometimes diminishes dramatically, without significant differences determined by the gender of the transmitting parent; however, the marked <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> and age dependence of the repeat length complicate interpretation of this observation [<a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>].</div></li></ul></div><div id="myotonic-d2.Clinical_Testing"><h5>Clinical Testing</h5><p><b>Targeted analysis for pathogenic variants.</b> The detection of abnormal <i>CNBP</i> alleles is complicated by the large size of the CCTG expansion and the presence of <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> (varying lengths of <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> due to somatic instability of the CCTG expansion). The detection rate of a <i>CNBP</i> CCTG expansion increases to more than 99% with use of a set of diagnostic tests that combines routine <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>, <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis, and the "PCR repeat-primed assay" [<a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>]. In 2012, best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2 were published. See <a class="bk_pop" href="#myotonic-d2.REF.kamsteeg.2012">Kamsteeg et al [2012]</a> (<a href="/pmc/articles/PMC3499739/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><div id="myotonic-d2.T.molecular_genetic_testing" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Myotonic Dystrophy Type 2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1466/table/myotonic-d2.T.molecular_genetic_testing/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myotonic-d2.T.molecular_genetic_testing_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Gene and Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CNBP</i></td><td headers="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>4</sup></td><td headers="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CCTG tetranucleotide repeat expansion in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1</td><td headers="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>6</sup></td><td headers="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td><td headers="hd_h_myotonic-d2.T.molecular_genetic_testing_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No reported cases&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="myotonic-d2.TF.1.1"><p class="no_margin">See <a href="/books/NBK1466/#myotonic-d2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="myotonic-d2.TF.1.2"><p class="no_margin">See <a href="#myotonic-d2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="myotonic-d2.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="myotonic-d2.TF.1.4"><p class="no_margin">May involve:<br />a. Routine <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>, which detects normal-sized alleles but not abnormal-sized alleles because it cannot amplify across the expansion;<br />b. <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis, which detects approximately 80% of expansions;<br />c. PCR repeat-primed assay, which aids in the detection of the CCTG repeat expansion. This assay, in which the primers are adjacent to and within the elongated CCTG repeat, differentially detects expanded alleles as a smear with varying repeat sizes but shows control alleles as a discrete band. The PCR repeat-primed assay products are probed with an internal probe to assure the necessary specificity.</p></div></dd><dt>5. </dt><dd><div id="myotonic-d2.TF.1.5"><p class="no_margin">Detection frequency varies by method used. When routine <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> analysis, <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis, and PCR repeat-primed assay are all used, the variant detection frequency is greater than 99%.</p></div></dd><dt>6. </dt><dd><div id="myotonic-d2.TF.1.6"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>7. </dt><dd><div id="myotonic-d2.TF.1.7"><p class="no_margin">Because of variation in the number of flanking TG and TCTG repeats and variation in the number of interruptions within the CCTG repeat tract, the precise number of CCTGs can only be determined by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. Although sequencing of some expanded alleles was necessary to demonstrate that only the CCTG portion of the complex repeat expands in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, sequencing to determine the specific CCTG repeat length is not useful for diagnostic purposes because most expansions are too long for efficient sequence analysis.</p></div></dd></dl></div></div></div></div><div id="myotonic-d2.Interpretation_of_Test_Resul"><h5>Interpretation of Test Results</h5><p><a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> analysis alone can exclude a diagnosis of DM2 if two normal-sized alleles are clearly resolvable.</p><p><a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA shows an expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in at least 80% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, but the size of the expansion is necessarily an estimate because of the marked <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> of the CCTG expansion and because the adjacent non-pathogenic repeats are polymorphic. Approximately 20% of expansions cannot be detected by Southern blot analysis because of a high degree of somatic mosaicism; alleles of varying lengths do not co-migrate during electrophoresis and become difficult to detect.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> repeat-primed assay can verify the presence of an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> that has expanded into the pathogenic range but does not allow determination of the total length of the expansion.</p></div></div></div><div id="myotonic-d2.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> If routine <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> analysis detects only one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, which occurs in 15% of normal individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> and in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, it is necessary to perform both <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis and the PCR repeat-primed assay to determine if the individual is homozygous for the normal-sized allele or has both a normal-sized allele and an expanded allele that fails to amplify by PCR because of its large size [<a class="bk_pop" href="#myotonic-d2.REF.liquori.2001.864">Liquori et al 2001</a>].</p><p><b>Predictive testing</b> for at-risk asymptomatic adult family members requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p></div></div><div id="myotonic-d2.Clinical_Characteristics"><h2 id="_myotonic-d2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="myotonic-d2.Clinical_Description"><h3>Clinical Description</h3><p>Myotonic dystrophy type 2 (DM2) is a multisystem disorder characterized by myotonia (90%) and muscle dysfunction (weakness, pain, and stiffness) (82%), as well as a consistent constellation of seemingly unrelated clinical features, including cardiac conduction defects (19%), iridescent posterior subcapsular cataracts (36%-78%, increasing with age), and a specific set of endocrine changes including insulin insensitivity (25%-75%, increasing with age) and testicular failure (29%-65%).</p><p>The onset of symptoms in individuals with DM2 is typically in the third decade, with the most common symptoms being muscle weakness and pain, although myotonia during the first decade has been reported [<a class="bk_pop" href="#myotonic-d2.REF.day.1999.19">Day et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>, <a class="bk_pop" href="#myotonic-d2.REF.udd.2011.443">Udd et al 2011</a>]. Note that unlike <a href="/books/n/gene/myotonic-d/">myotonic dystrophy type 1</a> (DM1), which can present in adulthood as a degenerative disorder or with variably severe <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> features, DM2 has not been associated with developmental abnormalities and thus does not cause severe childhood symptoms [<a class="bk_pop" href="#myotonic-d2.REF.udd.2011.443">Udd et al 2011</a>]. The absence of developmental defects in any <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members with DM2 is a reliable and clinically significant difference between the two forms of DM.</p><p><b>Muscle dysfunction.</b> Individuals with DM2 often come to medical attention because of muscle weakness, pain, and myotonia [<a class="bk_pop" href="#myotonic-d2.REF.ricker.1994.1448">Ricker et al 1994</a>, <a class="bk_pop" href="#myotonic-d2.REF.moxley.1996.87">Moxley 1996</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.1999.19">Day et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.ricker.1999.334">Ricker 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.ricker.1999.170">Ricker et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.thornton.1999.25">Thornton 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.harper.2001">Harper 2001</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>]. The muscles affected in the earliest stages of the disease are the neck flexors and finger flexors. Subsequently, weakness is seen in the elbow extensors and the hip flexors and extensors. Thirty percent of individuals have hip-muscle weakness that develops after age 50 years.</p><p>Facial weakness and weakness of the ankle dorsiflexors can also be present but are less common.</p><p>Myotonia, i.e., involuntary muscle contraction and delayed relaxation caused by muscle hyperexcitability, is present in almost all individuals with DM2 but only rarely causes severe symptoms.</p><p>Fluctuating or episodic muscle pain is reported by a majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and can be debilitating [<a class="bk_pop" href="#myotonic-d2.REF.george.2004.1938">George et al 2004</a>, <a class="bk_pop" href="#myotonic-d2.REF.auvinen.2008.3627">Auvinen et al 2008</a>, <a class="bk_pop" href="#myotonic-d2.REF.tieleman.2011.1820">Tieleman et al 2011</a>, <a class="bk_pop" href="#myotonic-d2.REF.suokas.2012.70">Suokas et al 2012</a>].</p><p><b>Multisystem features.</b> Posterior subcapsular iridescent cataracts can be seen on slit lamp examination as early as the second decade of life. The reported age of cataract extraction ranges from 28 to 74 years [<a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>].</p><p>Although cardiac involvement in individuals with DM2 appears more mild than in DM1 [<a class="bk_pop" href="#myotonic-d2.REF.meola.2002.89">Meola et al 2002</a>; <a class="bk_pop" href="#myotonic-d2.REF.sansone.2013.1147">Sansone et al 2013</a>], DM2 can be associated with atrioventricular and intraventricular conduction defects, arrhythmias, cardiomyopthy, and sudden death [<a class="bk_pop" href="#myotonic-d2.REF.nguyen.1988.662">Nguyen et al 1988</a>, <a class="bk_pop" href="#myotonic-d2.REF.colleran.1997.1494">Colleran et al 1997</a>, <a class="bk_pop" href="#myotonic-d2.REF.merino.1998.541">Merino et al 1998</a>, <a class="bk_pop" href="#myotonic-d2.REF.philips.1998.737">Philips et al 1998</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>, <a class="bk_pop" href="#myotonic-d2.REF.schoser.2004b.2402">Schoser et al 2004b</a>]. One study showed that DM2 is more commonly associated with left ventricular dysfunction than originally estimated [<a class="bk_pop" href="#myotonic-d2.REF.wahbi.2009.468">Wahbi et al 2009</a>].</p><p>Anesthetic complications have not been reported in individuals with DM2, and probably occur less frequently than in DM1, where intraoperative and postoperative cardiac arrhythmias, ventilatory suppression, and poor airway protection are recognized possible causes of significant morbidity and mortality [<a class="bk_pop" href="#myotonic-d2.REF.kirzinger.2010.842">Kirzinger et al 2010</a>, <a class="bk_pop" href="#myotonic-d2.REF.weingarten.2010.248">Weingarten et al 2010</a>].</p><p>Endocrine abnormalities described in individuals with DM2 include insulin-insensitive type 2 diabetes mellitus and testicular failure resulting in male infertility [<a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>, <a class="bk_pop" href="#myotonic-d2.REF.savkur.2004.1309">Savkur et al 2004</a>].</p><p>Individuals with DM2, like those with DM1, have a high incidence of hypogammaglobulinemia, with lower than normal levels of both IgG and IgM, although no associated clinical problems have been observed.</p><p>Central nervous system abnormalities reported in individuals with DM2 include white matter changes apparent on MRI and reduced cerebral blood flow in the frontal and temporal region apparent on PET scan [<a class="bk_pop" href="#myotonic-d2.REF.hund.1997.33">Hund et al 1997</a>, <a class="bk_pop" href="#myotonic-d2.REF.meola.1999.1042">Meola et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.franc.2012.483">Franc et al 2012</a>]. These anatomic changes appear to have some effect on cognition, behavior, and personality, although unlike DM1, DM2 has not been associated with intellectual disability [<a class="bk_pop" href="#myotonic-d2.REF.meola.2002.89">Meola et al 2002</a>, <a class="bk_pop" href="#myotonic-d2.REF.meola.2003.813">Meola et al 2003</a>].</p><p>A range of sleep disturbances including daytime sleepiness, insomnia, REM behavior disorders, and restless leg syndrome have been observed in case reports and case series of individuals with DM2 [<a class="bk_pop" href="#myotonic-d2.REF.day.1999.19">Day et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.bhat.2012.1207">Bhat et al 2012</a>, <a class="bk_pop" href="#myotonic-d2.REF.chokroverty.2012.2004">Chokroverty et al 2012</a>, <a class="bk_pop" href="#myotonic-d2.REF.shepard.2012.377">Shepard et al 2012</a>].</p><p>Gastrointestinal complications are common in DM2 and can include constipation, dysphagia, and abdominal pain [<a class="bk_pop" href="#myotonic-d2.REF.tieleman.2008.646">Tieleman et al 2008</a>].</p><p>In women with DM2, symptoms may worsen during pregnancy [<a class="bk_pop" href="#myotonic-d2.REF.day.1999.19">Day et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.newman.1999.144">Newman et al 1999</a>, <a class="bk_pop" href="#myotonic-d2.REF.rudniksch_neborn.2006.579">Rudnik-Sch&#x000f6;neborn et al 2006</a>]. Polyhydramnios, a recognized feature of DM1, has not been reported in individuals with DM2.</p><p><b>Cancer risk.</b> Several case reports have suggested an increased incidence for cancer in individuals with myotonic dystrophy. Recent retrospective studies have shown that individuals <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with myotonic dystrophy type 2 appear to be at a higher risk overall of developing cancer. Cancer in individuals with DM2 may involve the colon, brain, thyroid, pancreas, ovary, and endometrium [<a class="bk_pop" href="#myotonic-d2.REF.gadalla.2011.2480">Gadalla et al 2011</a>, <a class="bk_pop" href="#myotonic-d2.REF.win.2012.130">Win et al 2012</a>].</p></div><div id="myotonic-d2.GenotypePhenotype_Correlatio"><h3>Genotype-Phenotype Correlations</h3><p>No significant correlation exists between CCTG repeat size and age of onset of weakness or other measures of disease severity (e.g., age of cataract extraction). The observation that phenotypic features in individuals with CCTG repeat expansions in both <i>CNBP</i> alleles are as severe as those seen in their <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> sibs and parents further demonstrates that CCTG repeat number does not alter the clinical course [<a class="bk_pop" href="#myotonic-d2.REF.schoser.2004a.1868">Schoser et al 2004a</a>].</p><p>A correlation does exist between the repeat size and the age of the individual with DM2 at the time that the repeat size is measured, indicating that the repeat length increases with age [<a class="bk_pop" href="#myotonic-d2.REF.schneider.2000.383">Schneider et al 2000</a>, <a class="bk_pop" href="#myotonic-d2.REF.liquori.2001.864">Liquori et al 2001</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>].</p></div><div id="myotonic-d2.Penetrance"><h3>Penetrance</h3><p>Disease <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> reflects both an individual's sensitivity for his/her symptoms and a physician's ability to correctly identify and interpret signs of the disease. As <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families and their physicians become increasingly aware of the clinical features of DM2, penetrance approaches 100%.</p><p><b>Examination by experienced investigators.</b> In a study of 234 adults age 18 years or older examined by experienced investigators, all but one individual with a DM2 expansion were correctly classified as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. (A 50-year-old male was misclassified as unaffected, possibly the result of an incomplete examination.)</p><p>Family histories revealed the following:</p><ul><li class="half_rhythm"><div>Unexamined obligate heterozygotes were undiagnosed in the fifth and sixth decade of life or frequently were misdiagnosed as having "rheumatism," fibromyalgia, rheumatoid arthritis, inflammatory myopathy, atypical motor neuron disease, or metabolic myopathy.</div></li><li class="half_rhythm"><div>Disease elements other than musculoskeletal features, such as early-onset cataracts, testicular failure, and cardiac arrhythmias, were often identified, but not recognized as manifestations of DM2 [<a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>].</div></li></ul></div><div id="myotonic-d2.Anticipation"><h3>Anticipation</h3><p>Clinical features have been reported to worsen from generation to generation in families that participated in the original characterization of DM2 [<a class="bk_pop" href="#myotonic-d2.REF.schneider.2000.383">Schneider et al 2000</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>]. Data suggested that this was caused by <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> (the tendency for individuals in successive generations to present at an earlier age and/or with more severe manifestations) rather than bias of ascertainment (inadvertent inclusion of more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> younger-generation family members in the study).</p><ul><li class="half_rhythm"><div>However, <i>CNBP</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> revealed no overt <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> form of DM2 comparable to the congenital form of <a href="/books/n/gene/myotonic-d/">myotonic dystrophy type 1</a> (DM1), which established the role of <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> in that disease.</div></li><li class="half_rhythm"><div>Furthermore, the lack of correlation between disease severity and CCTG repeat length underscores the conclusion that intergenerational changes in repeat length would not be expected to worsen disease severity reliably.</div></li><li class="half_rhythm"><div>The lack of correlation between repeat length and disease severity is furthermore substantiated by the observation that individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for repeat expansions have clinical disease indistinguishable from that of their <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> sibs [<a class="bk_pop" href="#myotonic-d2.REF.schoser.2004a.1868">Schoser et al 2004a</a>].</div></li></ul></div><div id="myotonic-d2.Nomenclature"><h3>Nomenclature</h3><p>The International Myotonic Dystrophy Consortium (IDMC) and Online Mendelian Inheritance in Man (OMIM) both recognize that DM2 and proximal myotonic myopathy (PROMM) refer to the same condition. Individuals with PROMM were originally described as having some features of DM1 but without the characteristic <i>DMPK</i> <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion. DM2 was originally thought to be clinically distinct from PROMM because of apparent differences in the clinical descriptions of families with PROMM and DM2. However, most families with PROMM have now been shown to have the characteristic <i>CNBP</i> expansion observed in individuals with DM2.</p><p>Note: The term "PROMM" is still sometimes used to refer to the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> if the causative variant is unknown; however, when the diagnosis is established through <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>CNBP</i>, the more precise term "DM2" is preferable.</p><p>No other genetic causes of multisystem myotonic dystrophies have been confirmed, although their existence has been suggested. The International Myotonic Dystrophy Consortium has agreed that any newly identified multisystem myotonic dystrophies will be sequentially named as forms of myotonic dystrophy.</p><p>One family posited to have a myotonic dystrophy type 3 (DM3) [<a class="bk_pop" href="#myotonic-d2.REF.le_ber.2004.1979">Le Ber et al 2004</a>] has subsequently been shown to have an unusual presentation of Paget's disease with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> inclusion body myositis [<a class="bk_pop" href="#myotonic-d2.REF.udd.2006.403">Udd et al 2006</a>], also known as inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFTD) and caused by mutation of <i>VCP.</i> (See <a href="/books/n/gene/ibmpfd/">Inclusion Body Myopathy with Paget Disease of Bone and/or Frontotemporal Dementia</a>.)</p></div><div id="myotonic-d2.Prevalence"><h3>Prevalence</h3><p>Myotonic dystrophy is the most common adult form of muscular dystrophy, estimated to affect approximately one in 8,000 in the general population. The proportions of myotonic dystrophy caused by DM1 and DM2 are unknown. The incidence of DM2 remains unknown due to the range of clinical severity.</p><p>Prevalence appears to differ in various populations; however, few definitive demographic studies have been performed. A higher prevalence of DM2 is observed in Germany and Poland and in individuals of German or Polish descent [<a class="bk_pop" href="#myotonic-d2.REF.udd.2003.589">Udd et al 2003</a>]. In Finland, the incidence of DM2 (1:1,830) is higher than DM1 [<a class="bk_pop" href="#myotonic-d2.REF.suominen.2011.776">Suominen et al 2011</a>]. DM2 has been reported in Afghanistan and Sri Lanka but not in China, Japan, or sub-Saharan Africa.</p></div></div><div id="myotonic-d2.Genetically_Related_Allelic"><h2 id="_myotonic-d2_Genetically_Related_Allelic_">Genetically Related (Allelic) Disorders</h2><p>No <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> other than those discussed in this <i>GeneReview</i> is known to be associated with pathogenic variants in <i>CNBP</i>.</p></div><div id="myotonic-d2.Differential_Diagnosis"><h2 id="_myotonic-d2_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Multisystem myotonic myopathies.</b> The only definite causes of the myotonic dystrophy <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> to date are either an untranslated CTG expansion at the 3' untranslated region in <i>DMPK</i> (<a href="/books/n/gene/myotonic-d/">myotonic dystrophy type 1</a>, DM1) or a CCTG expansion in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 of <i>CNBP</i> (DM2). Definitive diagnosis of these two forms of myotonic dystrophy relies on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>Although routine clinical evaluation can reliably identify myotonic dystrophy, the true adult-onset forms of DM1 and DM2 cannot be reliably distinguished from each other using clinical criteria alone. The cataracts in individuals with DM1 and DM2 are indistinguishable. The most robust difference between DM1 and DM2 is that clubfeet, neonatal weakness and respiratory insufficiency, developmental delay / intellectual disability, craniofacial abnormalities, and childhood hypotonia and weakness have been reported in individuals with DM1 but not those with DM2. In addition, or possibly because of the presence of these <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> effects, adults with DM1 often have more weakness and myotonia than adults with DM2; individuals with DM1 tend to have more pronounced facial and bulbar weakness, muscle atrophy, cardiac involvement, and central nervous system abnormalities including central hypersomnia [<a class="bk_pop" href="#myotonic-d2.REF.meola.2002.89">Meola et al 2002</a>, <a class="bk_pop" href="#myotonic-d2.REF.ranum.2002.465">Ranum &#x00026; Day 2002</a>, <a class="bk_pop" href="#myotonic-d2.REF.ranum.2004.793">Ranum &#x00026; Day 2004</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2005.55">Day &#x00026; Ranum 2005</a>].</p><p>Previous reports of a multisystemic myotonic disorder that is not linked to the DM1 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> or the DM2 locus (i.e., "non-DM1, non-DM2 cases of PROMM") have been retracted after some family members were found to have a <i>CNBP</i> CCTG expansion, confirming the diagnosis of DM2 in those families [<a class="bk_pop" href="#myotonic-d2.REF.day.2003.657">Day et al 2003</a>]. Nonetheless, additional genetic causes of DM may exist.</p><p>The family described as having a novel multisystemic myotonic disorder ("DM3") [<a class="bk_pop" href="#myotonic-d2.REF.le_ber.2004.1979">Le Ber et al 2004</a>] has some features in common with DM1 and DM2 (cataracts and myotonia) but also has distinctly different neurologic abnormalities (motor neuron disease and spongiform encephalopathy); although the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in this family was initially thought to mirror myotonic dystrophy, the family has now been classified as having Paget's disease and <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> inclusion body myositis caused by a <i>VCP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#myotonic-d2.REF.udd.2006.403">Udd et al 2006</a>, <a class="bk_pop" href="#myotonic-d2.REF.weihl.2006.189">Weihl et al 2006</a>], a disorder pathophysiologically distinct from DM. (See <a href="/books/n/gene/ibmpfd/">Inclusion Body Myopathy with Paget Disease of Bone and/or Frontotemporal Dementia</a>.)</p><p><b>Distal myopathies.</b> The other major group in the differential diagnosis is distal myopathy (see <a class="figpopup" href="/books/NBK1466/table/myotonic-d2.T.distal_myopathies/?report=objectonly" target="object" rid-figpopup="figmyotonicd2Tdistalmyopathies" rid-ob="figobmyotonicd2Tdistalmyopathies">Table 2</a>).</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/udd/"><b>Udd distal myopathy</b></a> is characterized by weakness of ankle dorsiflexion and inability to walk on the heels after the age of 35 years. Disease progression is slow and muscle weakness remains confined to the anterior tibial muscles. The long-toe extensors become clinically involved after ten to 20 years, leading to foot drop and clumsiness when walking. Udd distal myopathy is caused by mutation of <i>TTN</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding titin [<a class="bk_pop" href="#myotonic-d2.REF.hackman.2002.492">Hackman et al 2002</a>].</div></li><li class="half_rhythm"><div><b>Nonaka early-adult-onset distal myopathy</b> with rimmed vacuoles usually begins in the second or third decade in the anterior compartment of the legs and in the toe extensors. Foot drop and a steppage gait are present with progression to loss of ambulation after 12 to 15 years. This is the same condition as quadriceps-sparing myopathy and is caused by mutation of <i>GNE</i> [<a class="bk_pop" href="#myotonic-d2.REF.nishino.2002.1689">Nishino et al 2002</a>]. See <a href="/books/n/gene/ibm/"><i>GNE</i>-Related Myopathy</a>.</div></li><li class="half_rhythm"><div><b>Zaspopathy</b> (Markesbery-Griggs late-onset distal myopathy) (OMIM <a href="https://omim.org/entry/609452" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609452</a>) is characterized by weakness of ankle dorsiflexion usually beginning in the late 40s, followed later by slow progression to the finger and wrist extensor muscles and to the intrinsic muscles of the hand. Eventually the proximal leg muscles become involved. This disease is caused by mutation of <i>LDB3</i> (also known as <i>ZASP</i>) [<a class="bk_pop" href="#myotonic-d2.REF.griggs.2007.1477">Griggs et al 2007</a>].</div></li><li class="half_rhythm"><div><b>MPD3,</b> a dominant distal myopathy, was described in Finland in a single family in which some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had onset in the upper limbs and others in the lower limbs; later, both upper and lower limbs are involved [<a class="bk_pop" href="#myotonic-d2.REF.haravuori.2004.183">Haravuori et al 2004</a>].</div></li><li class="half_rhythm"><div><b>Miyoshi early-adult-onset myopathy</b> begins in the posterior compartment of the legs, manifests as difficulty climbing stairs and walking on toes, and progresses to other distal and proximal muscles as with LGMD2B (see <a href="/books/n/gene/miyoshi/">Dysferlinopathy</a>). The serum CK concentration is usually more than 50 times normal.</div></li><li class="half_rhythm"><div><b>Welander distal myopathy</b> may sometimes have onset in the anterior compartment muscles of the lower legs, instead of the usual onset in the hand and finger extensors [<a class="bk_pop" href="#myotonic-d2.REF.von_tell.2002.544">von Tell et al 2002</a>]. Typically, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals experience weakness of the extensor of the index finger after age 40 years, followed by slow progression to the other finger extensors and to the anterior and posterior leg muscles.</div></li></ul><div id="myotonic-d2.T.distal_myopathies" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Distal Myopathies</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1466/table/myotonic-d2.T.distal_myopathies/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myotonic-d2.T.distal_myopathies_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mean Age at Onset (Years)</th><th id="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Initial Muscle Group Involved</th><th id="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum Creatine Kinase Concentration</th><th id="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle Biopsy</th><th id="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene (Locus)&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" colspan="6" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Autosomal dominant</b></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Welander distal myopathy (OMIM <a href="http://omim.org/entry/604454" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604454</a>)</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;40</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal upper limbs (finger &#x00026; wrist extensors)</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Normal or slightly increased</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rimmed vacuoles</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(2p13)</td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/udd/">Udd distal myopathy</a></td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;35</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Anterior compartment in legs</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x000b1; Rimmed vacuoles</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TTN</i></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Zaspopathy (Markesbery-Griggs late-onset distal myopathy) (OMIM <a href="https://omim.org/entry/609452" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609452</a>)</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;40</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Vacuolar &#x00026; myofibrillar myopathy</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LDB3</i> (also known as <i>ZASP)</i></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal myotilinopathy (OMIM <a href="https://omim.org/entry/609200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609200</a>)</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;40</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Posterior &#x0003e; anterior in legs</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Slightly increased</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vacuolar &#x00026; myofibrillar</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MYOT</i></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mpd1/">Laing early-onset distal myopathy</a> (MPD1)</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;20</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anterior compartment in legs and neck flexors</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to (rarely) moderately increased</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type 1 fiber atrophy in tibial anterior muscles; disproportion in proximal muscles</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MYH7</i></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal myopathy with vocal cord and pharyngeal signs (MPD2)</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35-60</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymmetric lower leg &#x00026; hands; dysphonia</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1-8 times</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rimmed vacuoles</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MATR3</i></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal myopathy with <i>pes cavus</i> and areflexia</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15-50</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anterior &#x00026; posterior lower leg; dysphonia &#x00026; dysphagia</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2-6 times</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophic, rimmed vacuoles</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(19p13)</td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">New Finnish distal myopathy (MPD3)</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;30</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hands or anterior lower leg</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1-4 times</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophic; rimmed vacuoles; eosinophilic inclusions</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(8p22-q11 and 12q13-q22)</td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5 hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" colspan="6" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Autosomal recessive</b></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ibm/">Nonaka early-adult-onset distal myopathy</a></td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15-20</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anterior compartment in legs</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;10 times</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rimmed vacuoles</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNE</i></td></tr><tr><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/miyoshi/">Miyoshi early-adult-onset myopathy</a></td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Posterior compartment in legs</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;10 times</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myopathic changes</td><td headers="hd_h_myotonic-d2.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DYSF</i></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#myotonic-d2.REF.udd.2001.561">Udd &#x00026; Griggs [2001]</a></p></div></dd><dt>1. </dt><dd><div id="myotonic-d2.TF.2.1"><p class="no_margin">Locus is given only if the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is not known.</p></div></dd></dl></div></div></div><p><b>Myotonia.</b> Electrical myotonia occurs in several conditions, but the presence of myotonia in multiple family members restricts diagnostic possibilities to either DM or to the nondystrophic myotonias, which are caused by mutation of chloride and sodium channel genes, resulting in <a href="/books/n/gene/myotonia-c/">myotonia congenita</a>, paramyotonia congenita, and <a href="/books/n/gene/hyper-pp/">hyperkalemic periodic paralysis</a>. Those conditions are not associated with the muscular dystrophy or multisystem features that typify DM1 and DM2 and can thus be distinguished on clinical grounds.</p><p><b>Other.</b> Occasionally, individuals with DM2 have been misdiagnosed as having atypical motor neuron disease [<a class="bk_pop" href="#myotonic-d2.REF.rotondo.2005.160">Rotondo et al 2005</a>], inflammatory myopathy, fibromyalgia, rheumatoid arthritis, or metabolic myopathy.</p></div><div id="myotonic-d2.Management"><h2 id="_myotonic-d2_Management_">Management</h2><div id="myotonic-d2.Evaluations_Following_Initia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with myotonic dystrophy type 2 (DM2), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Routine clinical evaluation of muscle strength and functional status</div></li><li class="half_rhythm"><div>Examination by an ophthalmologist familiar with DM iridescent posterior subcapsular cataracts in order to establish a baseline</div></li><li class="half_rhythm"><div>Initial cardiac evaluation including at minimum:</div><ul><li class="half_rhythm"><div>ECG to establish a baseline record for future comparison</div></li><li class="half_rhythm"><div>Holter monitoring or invasive electrophysiologic testing if the person is either symptomatic or shows significant rhythm or conduction abnormalities on routine ECG</div></li><li class="half_rhythm"><div>Because of the risk of cardiomyopathy, consideration of echocardiogram and possible cardiac MRI [<a class="bk_pop" href="#myotonic-d2.REF.spengos.2012.324">Spengos et al 2012</a>]</div></li></ul></li><li class="half_rhythm"><div>Baseline serologic testing including fasting lipid profiles, glucose, and glycosylated hemoglobin concentrations to assess for evidence of insulin insensitivity and diabetes mellitus</div></li><li class="half_rhythm"><div>Measurement of serum concentrations of testosterone and FSH in post-pubertal males to assess gonadal function</div></li><li class="half_rhythm"><div>Thyroid studies. While thyroid dysfunction has not been conclusively and causatively related to the DM2-causing pathogenic variants, hypothyroidism from any cause has been associated with increased muscle weakness and symptoms in individuals with DM2 [<a class="bk_pop" href="#myotonic-d2.REF.sansone.2000.165">Sansone et al 2000</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2005.55">Day &#x00026; Ranum 2005</a>].</div></li><li class="half_rhythm"><div>Measurement of the serum activities of CK, transaminases (AST and ALT), and &#x003b3;-glutamyltransferase (GGT). Serum activities of AST, ALT, and GGT are frequently elevated in individuals with DM2, although it is unclear whether the abnormal levels are hepatocellular or myogenic in origin. Determination of baseline abnormal transaminase and GGT activities resulting from DM2 can help prevent needless investigations of the liver.</div></li><li class="half_rhythm"><div>Serum protein electrophoresis and immunoprotein electrophoresis to establish a baseline, since the gamma fraction is frequently reduced in individuals with DM2 as a result of low levels of both IgG and IgM. Although these changes have not been associated with clinical problems, determination of abnormal immunoglobulin levels in persons with DM2 can establish individual baseline values and prevent misinterpretation of future studies demonstrating the hypogammaglobulinemia.</div></li></ul></div><div id="myotonic-d2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment guidelines for DM2 have been published [<a class="bk_pop" href="#myotonic-d2.REF.udd.2011.443">Udd et al 2011</a>].</p><p>A physiatrist, occupational therapist, or physical therapist can help determine the need for ankle-foot orthoses, wheelchairs, or other assistive devices as the disease progresses [<a class="bk_pop" href="#myotonic-d2.REF.johnson.1995.s104">Johnson et al 1995</a>].</p><p>Routine physical activity appears to be beneficial for maintaining muscle strength and endurance in persons with DM2, and as an aid to control musculoskeletal pain.</p><p>Myotonia is typically mild and rarely requires treatment [<a class="bk_pop" href="#myotonic-d2.REF.ricker.1999.334">Ricker 1999</a>], though use of mexilitene, which is very effective in controlling some forms of myotonia, has helped control muscle pain in some individuals with DM2.</p><p>The effectiveness of medications and combination of medications in pain management varies. No one medication has been consistently effective; medications that have been used with some success include mexilitene, gabapentin, nonsteroidal anti-inflammatory drugs (NSAIDS), low-dose thyroid replacement, low-dose steroids (e.g., 5 mg prednisone on alternate days), and tricyclic antidepressants. Low-dose narcotic analgesics, when used as part of a comprehensive pain management program, may help but may also lead to development of tolerance and escalating doses.</p><p>Consultation with a cardiologist is strongly recommended for individuals with cardiac symptoms or ECG evidence of arrhythmia because fatal arrhythmias can occur prior to the onset of other symptoms. ECG, Holter monitoring, and an echocardiogram should be performed to evaluate syncope, palpitations, and other symptoms of potential cardiac origin. More advanced, invasive electrophysiologic testing of the heart may be required [<a class="bk_pop" href="#myotonic-d2.REF.florek.1990.24">Florek et al 1990</a>, <a class="bk_pop" href="#myotonic-d2.REF.hawley.1991.259">Hawley et al 1991</a>]. Due to the increased risk for cardiomyopathy, echocardiography and possibly cardiac MRI should be considered.</p><p>The value of defibrillator placement is increasingly evident in individuals with DM2 who have overt arrhythmias, but the role of pacemaker/defibrillators in asymptomatic patients is yet to be determined [<a class="bk_pop" href="#myotonic-d2.REF.schoser.2004b.2402">Schoser et al 2004b</a>].</p><p>Cataracts can be removed if they impair vision. As compared to the more typical senile nuclear cataracts, direct ophthalmoscopy and even slit lamp examination can underestimate the functional significance of cataracts in individuals with DM2 because the alteration of vision depends on location, not just the number of subcapsular opacities.</p><p>Testosterone replacement therapy can be beneficial in males with symptomatic hypogonadism.</p><p>Direct gastrointestinal manifestations of DM2 are yet to be characterized, but some patients complain of postprandial abdominal pain, bloating, constipation, and diarrhea. As in <a href="/books/n/gene/myotonic-d/">myotonic dystrophy type 1</a> (DM1), some individuals respond to prokinetic agents such as metochlopromide (Reglan&#x02122;) and tegaserod (Zelnorm&#x02122;).</p></div><div id="myotonic-d2.Prevention_of_Secondary_Comp"><h3>Prevention of Secondary Complications</h3><p>Anesthetic risk may be increased in those with DM2; therefore, careful assessment of cardiac and respiratory function before and after surgery are recommended [<a class="bk_pop" href="#myotonic-d2.REF.veyckemans.2013.794">Veyckemans &#x00026; Scholtes 2013</a>].</p><p>Increased weakness in individuals with DM2 has been associated with hypothyroidism; thus, some strength may return if hypothyroidism is treated.</p></div><div id="myotonic-d2.Surveillance"><h3>Surveillance</h3><p>Annual ECG and echocardiogram or possible cardiac MRI is indicated to detect asymptomatic and progressive cardiac conduction defects and cardiomyopathy.</p><p>Some centers perform annual 24-hour Holter monitoring even in the absence of cardiac symptoms.</p><p>Fasting serum glucose concentration and glycosylated hemoglobin level should be measured annually.</p><p>Males should be tested for hypogonadism if they become increasingly fatigued or have reduced sexual energy, and should be tested every few years even without symptoms to see if they would benefit from replacement therapy.</p></div><div id="myotonic-d2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Increased weakness has been associated with the use of certain cholesterol-lowering medications. In these cases, some strength can return if statin-type cholesterol-lowering medications are eliminated.</p><p>Note: Not all individuals with DM2 have an adverse response to statin medications, and thus diagnosis of DM2 is not an absolute contraindication to use of these drugs.</p></div><div id="myotonic-d2.Evaluation_of_Relatives_at_R"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#myotonic-d2.Related_Genetic_Counseling_I">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="myotonic-d2.Therapies_Under_Investigatio"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="myotonic-d2.Genetic_Counseling"><h2 id="_myotonic-d2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="myotonic-d2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Myotonic dystrophy type 2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="myotonic-d2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>To date, all probands whose biological parents have been evaluated with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> have had one parent with a <i>CNBP</i> expansion.</div></li><li class="half_rhythm"><div>Probands with <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants have not been reported.</div></li><li class="half_rhythm"><div>The <i>CNBP</i> expansion shows size differences between generations in the same family. In general, the repeat size appears to contract when passed on to the subsequent generation and then to increase in size as the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual ages (see <a href="#myotonic-d2.Related_Genetic_Counseling_I">Related Genetic Counseling Issues</a>, <b>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a></b>). There is no maternal or paternal preference for contraction or expansion.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the parents.</div></li><li class="half_rhythm"><div>Sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual have a 50% chance of inheriting the <i>CNBP</i> expansion if one parent has the expansion.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with a <i>CNBP</i> expansion has a 50% chance of inheriting the expansion.</div></li><li class="half_rhythm"><div>The <i>CNBP</i> CCTG repeat tract tends to contract when passed from one generation to the next and then to increase in size as the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual ages.</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the status of the proband's parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members are at risk.</p></div><div id="myotonic-d2.Related_Genetic_Counseling_I"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <i>de novo</i> variant. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p>There is no correlation between the measured repeat size and disease severity; thus, age of onset or clinical course cannot be predicted from molecular genetic test results.</p><p><b>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a>.</b> The <i>CNBP</i> CCTG repeat expansion is highly unstable and tends to increase in size with age of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. The results of multiple tests performed on distinct peripheral blood samples drawn from affected individual at the same time or at different ages may differ in expansion size. In addition, an individual may have more than one expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> size detectable by <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis in a single sample of peripheral blood. Neither the size of a predominant allele nor the total number of different detectable expansions in a single sample can predict disease severity, age of onset, or clinical symptoms of the condition.</p><p><b>Testing of at-risk asymptomatic adults.</b> Testing of at-risk asymptomatic adults is possible using the techniques described in <a href="#myotonic-d2.Molecular_Genetic_Testing">Molecular Genetic Testing</a>. Predictive testing can determine whether an individual has a <i>CNBP</i> expansion, and thus whether that individual is at risk of developing the disease. The repeat size cannot predict age of onset, severity, or clinical symptoms. An <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member should be tested prior to offering testing to at-risk family members to confirm the presence of a <i>CNBP</i> expansion in the family. Predictive testing should be accompanied by <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> to assure that individuals are aware of the limitations of the molecular genetic test and the possible risks associated with predictive testing.</p><p><b>Testing of at-risk individuals younger than age 18 years.</b> Testing of at-risk asymptomatic individuals younger than age 18 years is not recommended for adult-onset conditions in which there is no known effective treatment that prevents the disease or improves the outcome. Individuals younger than age 18 years who are symptomatic usually benefit from having a specific diagnosis established. See also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>&#x000a0;(including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="myotonic-d2.Prenatal_Testing_and_Preimpl"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CNBP</i> pathogenic expansion has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="myotonic-d2.Resources"><h2 id="_myotonic-d2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>MDF Clinic Visit Planner</b></div><div><i>Planner that enables families to discuss upcoming clinic visits and jot down important questions and information to help ensure that it was shared at the appointment.</i></div><div><a href="https://www.myotonic.org/sites/default/files/pages/files/MDF%20ClinicVisitPlannerv5.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MDF Clinic Visit Planner</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Myotonic%20Dystrophy%20type%202&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myotonic dystrophy type 2</a></div></li><li class="half_rhythm"><div><b>Myotonic Dystrophy: Making an Informed Choice About Genetic Testing</b></div><div><i>Booklet providing information about Myotonic Dystrophy and genetic testing (PDF file)</i></div><div>University of Washington Medical Center, Medical Genetics and Neurology</div><div>Seattle WA </div><div><a href="http://depts.washington.edu/neurolog/images/neurogenetics/myotonic.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">depts.washington.edu/neurolog/images/neurogenetics/myotonic.pdf</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=myotonicdystrophytype1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myotonic dystrophy</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy UK</b></div><div>61A Great Suffolk Street</div><div>London SE1 0BU </div><div>United Kingdom</div><div><b>Phone:</b> 0800 652 6352 (toll-free); 020 7803 4800</div><div><b>Email:</b> info@musculardystrophyuk.org</div><div><a href="http://www.musculardystrophyuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.musculardystrophyuk.org</a></div></li><li class="half_rhythm"><div><b>Myotonic Dystrophy Family Registry (MDFR)</b></div><div><b>Phone:</b> 602-435-7496</div><div><b>Email:</b> coordinator@myotonicregistry.org</div><div><a href="https://myotonicregistry.patientcrossroads.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">myotonicregistry.patientcrossroads.org</a></div></li><li class="half_rhythm"><div><b>National Registry of Myotonic Dystrophy and FSHD Patients and Family Members</b></div><div>National Registry of Myotonic Dystrophy and FSHD</div><div>601 Elmwood Avenue</div><div>Box 673</div><div>Rochester NY 14642</div><div><b>Phone:</b> 888-925-4302</div><div><b>Fax:</b> 585-273-1255</div><div><b>Email:</b> dystrophy_registry@urmc.rochester.edu</div><div><a href="http://www.urmc.rochester.edu/neurology/national-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">National Registry for Myotonic Dystrophy (DM) &#x00026; Facioscapulohumeral Dystrophy (FSHD)</a></div></li></ul></div><div id="myotonic-d2.Molecular_Genetics"><h2 id="_myotonic-d2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="myotonic-d2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Myotonic Dystrophy Type 2: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1466/table/myotonic-d2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myotonic-d2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_myotonic-d2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_myotonic-d2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_myotonic-d2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_myotonic-d2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_myotonic-d2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_myotonic-d2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_myotonic-d2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7555" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CNBP</i></a></td><td headers="hd_b_myotonic-d2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7555" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3q21<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_myotonic-d2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P62633" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cellular nucleic acid-binding protein</a></td><td headers="hd_b_myotonic-d2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CNBP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CNBP database</a></td><td headers="hd_b_myotonic-d2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CNBP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CNBP</a></td><td headers="hd_b_myotonic-d2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CNBP[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CNBP</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="myotonic-d2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="myotonic-d2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Myotonic Dystrophy Type 2 (<a href="/omim/116955,602668" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1466/table/myotonic-d2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myotonic-d2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/116955" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">116955</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CCHC-TYPE ZINC FINGER NUCLEIC ACID-BINDING PROTEIN; CNBP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602668" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602668</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MYOTONIC DYSTROPHY 2; DM2</td></tr></tbody></table></div></div><div id="myotonic-d2.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The clinical and molecular parallels of <a href="/books/n/gene/myotonic-d/">myotonic dystrophy type 1</a> (DM1) and myotonic dystrophy type 2 (DM2) strongly suggest that the untranslated RNAs that contain the repeat expansion are responsible for the pathologic features common to both disorders.</p><p>The pathogenesis of both DM1 and DM2 can be explained by a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> RNA mechanism in which the CUG and CCUG repeats, respectively, alter cellular function, including alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of various genes [<a class="bk_pop" href="#myotonic-d2.REF.tapscott.2001.816">Tapscott &#x00026; Thornton 2001</a>, <a class="bk_pop" href="#myotonic-d2.REF.ranum.2002.465">Ranum &#x00026; Day 2002</a>, <a class="bk_pop" href="#myotonic-d2.REF.ranum.2004.793">Ranum &#x00026; Day 2004</a>, <a class="bk_pop" href="#myotonic-d2.REF.day.2005.55">Day &#x00026; Ranum 2005</a>]. Both DM1 and DM2 have RNA foci containing RNA of the abnormally expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> that colocalize with several forms of the RNA-binding protein muscleblind (MBNL, MBLL, and MBXL) [<a class="bk_pop" href="#myotonic-d2.REF.mankodi.2001.a211">Mankodi et al 2001</a>, <a class="bk_pop" href="#myotonic-d2.REF.fardaei.2002.805">Fardaei et al 2002</a>].</p><p>Dysregulation of muscleblind and of the RNA-binding protein CUG-BP (encoded by <i>CNBP</i>) subsequently alters <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of various downstream genes. Increased CUG-BP RNA results in missplicing of cardiac troponin T, the insulin receptor, and the chloride channel, possibly contributing to the cardiac involvement, insulin insensitivity, and myotonia, respectively [<a class="bk_pop" href="#myotonic-d2.REF.philips.1998.737">Philips et al 1998</a>, <a class="bk_pop" href="#myotonic-d2.REF.mankodi.2001.a211">Mankodi et al 2001</a>, <a class="bk_pop" href="#myotonic-d2.REF.savkur.2001.40">Savkur et al 2001</a>]. Downstream effects of abnormal insulin receptor splicing in both DM1 and DM2 correlate with the insulin insensitivity in both disorders [<a class="bk_pop" href="#myotonic-d2.REF.savkur.2004.1309">Savkur et al 2004</a>]. Knockout of muscleblind in mice leads to the myotonia, cataracts, and myopathy characteristic of DM1 and DM2 [<a class="bk_pop" href="#myotonic-d2.REF.kanadia.2003.1978">Kanadia et al 2003</a>].</p><p><b>Gene structure.</b> The <i>CNBP</i> (formerly <i>ZNF9</i>) CCTG repeat is part of a complex repeat motif with the overall configuration (TG)n(TCTG)n(CCTG)n. In normal <i>CNBP</i> alleles, the CCTG repeat contains nucleotide interruptions. The longest known normal <i>CNBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, in which the overall repeat motif is 176 bp in length, includes 26 CCTG repeats with two interruptions [<a class="bk_pop" href="#myotonic-d2.REF.liquori.2001.864">Liquori et al 2001</a>]. Such nucleotide interruptions are similar to those seen in normal-length alleles of genes that cause other <a class="def" href="/books/n/gene/glossary/def-item/nucleotide-repeat/">nucleotide repeat</a> disorders (<a href="/books/n/gene/sca1/">spinocerebellar ataxia type 1</a> and <a href="/books/n/gene/fragilex/"><i>FMR1</i>-related disorders</a>) [<a class="bk_pop" href="#myotonic-d2.REF.chung.1993.254">Chung et al 1993</a>, <a class="bk_pop" href="#myotonic-d2.REF.kunst.1994.853">Kunst &#x00026; Warren 1994</a>].</p><p><i>CNBP</i> is widely expressed. It shares no functional similarity to any genes at the DM1 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>, including the dystrophica myotonica-protein kinase <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>DMPK</i>), within the 3'-untranslated region of which the DM1 CTG expansion exists. Likewise, none of the genes in the DM2 region share similarity to genes in the DM1 region. The lack of similar genes at the two loci further indicates that the causative variants result in pathogenic RNA expansions rather than alteration of gene expression or gene products. See <a href="/books/NBK1466/#myotonic-d2.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of gene and protein information.</p><p><b>Pathogenic variants.</b> DM2 is caused by a single mutational mechanism of a CCTG tetranucleotide repeat expansion of more than 75 (overall repeat lengths greater than 372 bp). The expanded repeat length ranges from 372 bp to more than 44,000 bp (equivalent to a range of 75 to &#x0003e;11,000 repeats), although the actual pathogenic threshold has not been determined because the repeat tract is highly unstable and displays marked <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a>. The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with the smallest repeat expansion also had a second large expansion; it remains unknown if both or just one is pathogenic. The CCTG repeat that is expanded in DM2 lies in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 of <i>CNBP</i> and is transcribed into RNA but not translated into protein.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>CNBP</i> encodes a 19,463-dalton cellular nucleic acid-binding protein with 177 amino acids (<a href="/protein/NP_003409.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003409.1</a>) [<a class="bk_pop" href="#myotonic-d2.REF.pellizzoni.1997.264">Pellizzoni et al 1997</a>, <a class="bk_pop" href="#myotonic-d2.REF.pellizzoni.1998.593">Pellizzoni et al 1998</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The CCTG repeat that is expanded in DM2 is transcribed into RNA but is not translated into protein. There is no evidence of <i>CNBP</i> <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> in DM2 [<a class="bk_pop" href="#myotonic-d2.REF.margolis.2006.1808">Margolis et al 2006</a>].</p></div></div><div id="myotonic-d2.References"><h2 id="_myotonic-d2_References_">References</h2><div id="myotonic-d2.Published_Guidelines__Consen"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.kamsteeg.2012">Kamsteeg EJ, Kress W, Catalli C, Hertz JM, Witsch-Baumgartner M, Buckley MF, van Engelen BGM, Schwartz M, Scheffer H. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Available <a href="/pmc/articles/PMC3499739/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 4-29-19. [<a href="/pmc/articles/PMC3499739/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3499739</span></a>] [<a href="/pubmed/22643181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22643181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.udd.2011.443">Udd B, Meola G, Krahe R, Wansink DG, Bassez G, Kress W, Schoser B, Moxley R. Myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3&#x02013;5 December 2010, Naarden, The Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2011;<span class="ref-vol">21</span>:443–50.</span> [<a href="/pubmed/21543227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21543227</span></a>]</div></li></ul></div><div id="myotonic-d2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.auvinen.2008.3627">Auvinen S, Suominen T, Hannonen P, Bachinski LL, Krahe R, Udd B. Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. <span><span class="ref-journal">Arthritis Rheum. </span>2008;<span class="ref-vol">58</span>:3627–31.</span> [<a href="/pmc/articles/PMC2585600/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2585600</span></a>] [<a href="/pubmed/18975316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18975316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.bhat.2012.1207">Bhat S, Sander HW, Grewal RP, Chokroverty S. Sleep disordered breathing and other sleep dysfunction in myotonic dystrophy type 2. <span><span class="ref-journal">Sleep Med. </span>2012;<span class="ref-vol">13</span>:1207–8.</span> [<a href="/pubmed/22959494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22959494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.chokroverty.2012.2004">Chokroverty S, Bhat S, Rosen D, Farheen A. REM behavior disorder in myotonic dystrophy type 2. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">78</span>:2004.</span> [<a href="/pubmed/22689737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22689737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.chung.1993.254">Chung MY, Ranum LP, Duvick LA, Servadio A, Zoghbi HY, Orr HT. Evidence for a mechanism predisposing to intergenerational CAG repeat instability in spinocerebellar ataxia type I. <span><span class="ref-journal">Nat Genet. </span>1993;<span class="ref-vol">5</span>:254–8.</span> [<a href="/pubmed/8275090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8275090</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.colleran.1997.1494">Colleran JA, Hawley RJ, Pinnow EE, Kokkinos PF, Fletcher RD. Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy. <span><span class="ref-journal">Am J Cardiol. </span>1997;<span class="ref-vol">80</span>:1494–7.</span> [<a href="/pubmed/9399734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9399734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.day.2005.55">Day JW, Ranum LP. Genetics and molecular pathogenesis of the myotonic dystrophies. <span><span class="ref-journal">Curr Neurol Neurosci Rep. </span>2005;<span class="ref-vol">5</span>:55–9.</span> [<a href="/pubmed/15676109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15676109</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.dabby.2011.745">Dabby R, Sadeh M, Herman O, Leibou L, Kremer E, Mordechai S, Watemberg N, Frand J. Clinical, electrophysiologic and pathologic findings in 10 patients with myotonic dystrophy 2. <span><span class="ref-journal">Isr Med Assoc J. </span>2011;<span class="ref-vol">13</span>:745–7.</span> [<a href="/pubmed/22332444" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22332444</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.day.2003.657">Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">60</span>:657–64.</span> [<a href="/pubmed/12601109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12601109</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.day.1999.19">Day JW, Roelofs R, Leroy B, Pech I, Benzow K, Ranum LP. Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). <span><span class="ref-journal">Neuromuscul Disord. </span>1999;<span class="ref-vol">9</span>:19–27.</span> [<a href="/pubmed/10063831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10063831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.fardaei.2002.805">Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, Harper PS, Brook JD. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:805–14.</span> [<a href="/pubmed/11929853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11929853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.florek.1990.24">Florek RC, Triffon DW, Mann DE, Ringel SP, Reiter MJ. Electrocardiographic abnormalities in patients with myotonic dystrophy. <span><span class="ref-journal">West J Med. </span>1990;<span class="ref-vol">153</span>:24–7.</span> [<a href="/pmc/articles/PMC1002461/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1002461</span></a>] [<a href="/pubmed/2202157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2202157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.franc.2012.483">Franc DT, Muetzel RL, Robinson PR, Rodriguez CP, Dalton JC, Naughton CE, Mueller BA, Wozniak JR, Lim KO, Day JW. Cerebral and muscle MRI abnormalities in myotonic dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>2012;<span class="ref-vol">22</span>:483–91.</span> [<a href="/pmc/articles/PMC3350604/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3350604</span></a>] [<a href="/pubmed/22290140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22290140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.gadalla.2011.2480">Gadalla SM, Lund M, Pfeiffer RM, G&#x000f8;rtz S, Mueller CM, Moxley RT III, Kristinsson SY, Bj&#x000f6;rkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH. Cancer risk among patients with myotonic muscular dystrophy. <span><span class="ref-journal">JAMA. </span>2011;<span class="ref-vol">306</span>:2480–6.</span> [<a href="/pmc/articles/PMC3286183/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3286183</span></a>] [<a href="/pubmed/22166607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22166607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.george.2004.1938">George A, Schneider-Gold C, Zier S, Reiners K, Sommer C. Musculoskeletal pain in patients with myotonic dystrophy type 2. <span><span class="ref-journal">Arch Neurol. </span>2004;<span class="ref-vol">61</span>:1938–42.</span> [<a href="/pubmed/15596616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15596616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.giagnacovo.2012.699">Giagnacovo M, Malatesta M, Cardani R, Meola G, Pellicciari C. Nuclear ribonucleoprotein-containing foci increase in size in non-dividing cells from patients with myotonic dystrophy type 2. <span><span class="ref-journal">Histochem Cell Biol. </span>2012;<span class="ref-vol">138</span>:699–707.</span> [<a href="/pubmed/22706481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22706481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.griggs.2007.1477">Griggs R, Vihola A, Hackman P, Talvinen K, Haravuori H, Faulkner G, Eymard B, Richard I, Selcen D, Engel A, Carpen O, Udd B. Zaspopathy in a large classic late-onset distal myopathy family. <span><span class="ref-journal">Brain. </span>2007;<span class="ref-vol">130</span>:1477–84.</span> [<a href="/pubmed/17337483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17337483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.hackman.2002.492">Hackman P, Vihola A, Haravuori H, Marchand S, Sarparanta J, De Seze J, Labeit S, Witt C, Peltonen L, Richard I, Udd B. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:492–500.</span> [<a href="/pmc/articles/PMC379188/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379188</span></a>] [<a href="/pubmed/12145747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12145747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.haravuori.2004.183">Haravuori H, Siitonen HA, Mahjneh I, Hackman P, Lahti L, Somer H, Peltonen L, Kestil&#x000e4; M, Udd B. Linkage to two separate loci in a family with a novel distal myopathy phenotype (MPD3). <span><span class="ref-journal">Neuromuscul Disord. </span>2004;<span class="ref-vol">14</span>:183–7.</span> [<a href="/pubmed/15036327" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15036327</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.harper.2001">Harper PS. <em>Myotonic Dystrophy</em>. London, UK: WB Saunders; 2001.</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.hawley.1991.259">Hawley RJ, Milner MR, Gottdiener JS, Cohen A. Myotonic heart disease: a clinical follow-up. <span><span class="ref-journal">Neurology. </span>1991;<span class="ref-vol">41</span>:259–62.</span> [<a href="/pubmed/1992371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1992371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.hund.1997.33">Hund E, Jansen O, Koch MC, Ricker K, Fogel W, Niedermaier N, Otto M, Kuhn E, Meinck HM. Proximal myotonic myopathy with MRI white matter abnormalities of the brain. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">48</span>:33–7.</span> [<a href="/pubmed/9008490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9008490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.johnson.1995.s104">Johnson ER, Abresch RT, Carter GT, Kilmer DD, Fowler WM, Sigford BJ, Wanlass RL. Profiles of neuromuscular diseases. Myotonic dystrophy. <span><span class="ref-journal">Am J Phys Med Rehabil. </span>1995;<span class="ref-vol">74</span>:S104–16.</span> [<a href="/pubmed/7576418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7576418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.kanadia.2003.1978">Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS. A muscleblind knockout model for myotonic dystrophy. <span><span class="ref-journal">Science. </span>2003;<span class="ref-vol">302</span>:1978–80.</span> [<a href="/pubmed/14671308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14671308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.kamsteeg.2012.1203">Kamsteeg E-J, Kress W, Catalli C, Hertz JM, Witsch-Baumgartner M, Buckley MF, van Engelen Baziel GM, Schwartz M, Scheffer H. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:1203–8.</span> [<a href="/pmc/articles/PMC3499739/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3499739</span></a>] [<a href="/pubmed/22643181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22643181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.kirzinger.2010.842">Kirzinger L, Schmidt A, Kornblum C, Schneider-Gold C, Kress W, Schoser B. Side effects of anesthesia in DM2 as compared to DM1: a comparative retrospective study. <span><span class="ref-journal">Eur J Neurol. </span>2010 Jun 1;<span class="ref-vol">17</span>:842–5.</span> [<a href="/pubmed/20100232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20100232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.kunst.1994.853">Kunst CB, Warren ST. Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. <span><span class="ref-journal">Cell. </span>1994;<span class="ref-vol">77</span>:853–61.</span> [<a href="/pubmed/7911740" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7911740</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.le_ber.2004.1979">Le Ber I, Martinez M, Campion D, Laquerriere A, Betard C, Bassez G, Girard C, Saugier-Veber P, Raux G, Sergeant N, Magnier P, Maisonobe T, Eymard B, Duyckaerts C, Delacourte A, Frebourg T, Hannequin D. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. <span><span class="ref-journal">Brain. </span>2004;<span class="ref-vol">127</span>:1979–92.</span> [<a href="/pubmed/15215218" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15215218</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.liquori.2003.849">Liquori CL, Ikeda Y, Weatherspoon M, Ricker K, Schoser BG, Dalton JC, Day JW, Ranum LP. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">73</span>:849–62.</span> [<a href="/pmc/articles/PMC1180607/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180607</span></a>] [<a href="/pubmed/14505273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14505273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.liquori.2001.864">Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. <span><span class="ref-journal">Science. </span>2001;<span class="ref-vol">293</span>:864–7.</span> [<a href="/pubmed/11486088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11486088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.mankodi.2001.a211">Mankodi A, Takahashi M, Beck C, Cannon S, Thornton CA. Myotonia is associated with loss of transmembrane chloride conductance and aberrant splicing of Clcn1, the skeletal muscle chloride channel, in a transgenic model of myotonic dystrophy (DM1). <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:A211.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.margolis.2006.1808">Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LP. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:1808–15.</span> [<a href="/pubmed/16624843" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16624843</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.meola.2002.89">Meola G, Sansone V, Marinou K, Cotelli M, Moxley RT, Thornton CA, De Ambroggi L. Proximal myotonic myopathy: a syndrome with a favourable prognosis? <span><span class="ref-journal">J Neurol Sci. </span>2002;<span class="ref-vol">193</span>:89–96.</span> [<a href="/pubmed/11790388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11790388</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.meola.1999.1042">Meola G, Sansone V, Perani D, Colleluori A, Cappa S, Cotelli M, Fazio F, Thornton CA, Moxley RT. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">53</span>:1042–50.</span> [<a href="/pubmed/10496264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10496264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.meola.2003.813">Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, Cattaneo E, Cotelli M, Gobbo C, Fazio F, Siciliano G, Mancuso M, Vitelli E, Zhang S, Krahe R, Moxley RT. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). <span><span class="ref-journal">Neuromuscul Disord. </span>2003;<span class="ref-vol">13</span>:813–21.</span> [<a href="/pubmed/14678804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14678804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.merino.1998.541">Merino JL, Carmona JR, Fernandez-Lozano I, Peinado R, Basterra N, Sobrino JA. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation. <span><span class="ref-journal">Circulation. </span>1998;<span class="ref-vol">98</span>:541–6.</span> [<a href="/pubmed/9714111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9714111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.moxley.1996.87">Moxley RT 3rd. Proximal myotonic myopathy: mini-review of a recently delineated clinical disorder. <span><span class="ref-journal">Neuromuscul Disord. </span>1996;<span class="ref-vol">6</span>:87–93.</span> [<a href="/pubmed/8664567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8664567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.newman.1999.144">Newman B, Meola G, O'Donovan DG, Schapira AH, Kingston H. Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. <span><span class="ref-journal">Neuromuscul Disord. </span>1999;<span class="ref-vol">9</span>:144–9.</span> [<a href="/pubmed/10382907" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10382907</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.nguyen.1988.662">Nguyen HH, Wolfe JT, Holmes DR, Edwards WD. Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases. <span><span class="ref-journal">J Am Coll Cardiol. </span>1988;<span class="ref-vol">11</span>:662–71.</span> [<a href="/pubmed/3278037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3278037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.nishino.2002.1689">Nishino I, Noguchi S, Murayama K, Driss A, Sugie K, Oya Y, Nagata T, Chida K, Takahashi T, Takusa Y, Ohi T, Nishimiya J, Sunohara N, Ciafaloni E, Kawai M, Aoki M, Nonaka I. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:1689–93.</span> [<a href="/pubmed/12473753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12473753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.pellizzoni.1997.264">Pellizzoni L, Lotti F, Maras B, Pierandrei-Amaldi P. Cellular nucleic acid binding protein binds a conserved region of the 5' UTR of Xenopus laevis ribosomal protein mRNAs. <span><span class="ref-journal">J Mol Biol. </span>1997;<span class="ref-vol">267</span>:264–75.</span> [<a href="/pubmed/9096224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9096224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.pellizzoni.1998.593">Pellizzoni L, Lotti F, Rutjes SA, Pierandrei-Amaldi P. Involvement of the Xenopus laevis Ro60 autoantigen in the alternative interaction of La and CNBP proteins with the 5'UTR of L4 ribosomal protein mRNA. <span><span class="ref-journal">J Mol Biol. </span>1998;<span class="ref-vol">281</span>:593–608.</span> [<a href="/pubmed/9710533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9710533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.philips.1998.737">Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. <span><span class="ref-journal">Science. </span>1998;<span class="ref-vol">280</span>:737–41.</span> [<a href="/pubmed/9563950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9563950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.pisani.2008.1405">Pisani V, Panico MB, Terracciano C, Bonifazi E, Meola G, Novelli G, Bernardi G, Angelini C, Massa R. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. <span><span class="ref-journal">Muscle Nerve. </span>2008;<span class="ref-vol">38</span>:1405–11.</span> [<a href="/pubmed/18816606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18816606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.ranum.2002.465">Ranum LP, Day JW. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. <span><span class="ref-journal">Curr Neurol Neurosci Rep. </span>2002;<span class="ref-vol">2</span>:465–70.</span> [<a href="/pubmed/12169228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12169228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.ranum.2004.793">Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:793–804.</span> [<a href="/pmc/articles/PMC1181975/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1181975</span></a>] [<a href="/pubmed/15065017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15065017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.ricker.1999.334">Ricker K. Myotonic dystrophy and proximal myotonic myophathy. <span><span class="ref-journal">J Neurol. </span>1999;<span class="ref-vol">246</span>:334–8.</span> [<a href="/pubmed/10399862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10399862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.ricker.1999.170">Ricker K, Grimm T, Koch MC, Schneider C, Kress W, Reimers CD, Schulte-Mattler W, Mueller-Myhsok B, Toyka KV, Mueller CR. Linkage of proximal myotonic myopathy to chromosome 3q. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">52</span>:170–1.</span> [<a href="/pubmed/9921867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9921867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.ricker.1994.1448">Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Otto M, Heine R, Moxley RT. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. <span><span class="ref-journal">Neurology. </span>1994;<span class="ref-vol">44</span>:1448–52.</span> [<a href="/pubmed/8058147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8058147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.rotondo.2005.160">Rotondo G, Sansone V, Cardani R, Mancinelli E, Krahe R, Stangalini D, Meola G. Proximal myotonic dystrophy mimicking progressive muscular atrophy. <span><span class="ref-journal">Eur J Neurol. </span>2005;<span class="ref-vol">12</span>:160–1.</span> [<a href="/pubmed/15679706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15679706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.rudniksch_neborn.2006.579">Rudnik-Sch&#x000f6;neborn S, Schneider-Gold C, Raabe U, Kress W, Zerres K, Schoser BG. Outcome and effect of pregnancy in myotonic dystrophy type 2. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">66</span>:579–80.</span> [<a href="/pubmed/16505316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16505316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.sansone.2013.1147">Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, Bandera F, De Ambroggi L, Meola G. The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): Long-term outcomes. <span><span class="ref-journal">Int J Cardiol. </span>2013;<span class="ref-vol">168</span>:1147–53.</span> [<a href="/pubmed/23266299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23266299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.sansone.2000.165">Sansone V, Griggs RC, Moxley RT. Hypothyroidism unmasking proximal myotonic myopathy. <span><span class="ref-journal">Neuromuscul Disord. </span>2000;<span class="ref-vol">10</span>:165–72.</span> [<a href="/pubmed/10734262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10734262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.savkur.2001.40">Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:40–7.</span> [<a href="/pubmed/11528389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11528389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.savkur.2004.1309">Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, Ranum LP, Day JW. Insulin receptor splicing alteration in myotonic dystrophy type 2. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:1309–13.</span> [<a href="/pmc/articles/PMC1182097/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1182097</span></a>] [<a href="/pubmed/15114529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15114529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.schneider.2000.383">Schneider C, Ziegler A, Ricker K, Grimm T, Kress W, Reimers CD, Meinck H, Reiners K, Toyka KV. Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">55</span>:383–8.</span> [<a href="/pubmed/10932272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10932272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.schoser.2004a.1868">Schoser BG, Kress W, Walter MC, Halliger-Keller B, Lochmuller H, Ricker K. Homozygosity for CCTG mutation in myotonic dystrophy type 2. <span><span class="ref-journal">Brain. </span>2004a;<span class="ref-vol">127</span>:1868–77.</span> [<a href="/pubmed/15231584" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15231584</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.schoser.2004b.2402">Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Durre J, Bultmann B, Kress W, Day JW, Ranum LP. Sudden cardiac death in myotonic dystrophy type 2. <span><span class="ref-journal">Neurology. </span>2004b;<span class="ref-vol">63</span>:2402–4.</span> [<a href="/pubmed/15623712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15623712</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.schoser.2004c.275">Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, Koch MC, Pongratz DE, Toyka KV, Lochmuller H, Ricker K. Muscle pathology in 57 patients with myotonic dystrophy type 2. <span><span class="ref-journal">Muscle Nerve. </span>2004c;<span class="ref-vol">29</span>:275–81.</span> [<a href="/pubmed/14755494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14755494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.shepard.2012.377">Shepard P, Lam EM, St Louis EK, Dominik J. Sleep disturbances in myotonic dystrophy type 2. <span><span class="ref-journal">Eur Neurol. </span>2012;<span class="ref-vol">68</span>:377–80.</span> [<a href="/pmc/articles/PMC4259012/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4259012</span></a>] [<a href="/pubmed/23108384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23108384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.spengos.2012.324">Spengos K, Gialafos E, Vassilopoulou S, Toulas P, Manta P. Delayed contrast enhancement on cardiac MRI unmasks subclinical cardiomyopathy in a case of myotonic dystrophy type 2. <span><span class="ref-journal">Hellenic J Cardiol. </span>2012;<span class="ref-vol">53</span>:324–6.</span> [<a href="/pubmed/22796821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22796821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.suokas.2012.70">Suokas KI, Haanpaa M, Kautiainen H, Udd B, Hietaharju AJ. Pain in patients with myotonic dystrophy type 2: a postal survey in finland. <span><span class="ref-journal">Muscle Nerve. </span>2012;<span class="ref-vol">45</span>:70–4.</span> [<a href="/pubmed/22190310" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22190310</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.suominen.2011.776">Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, Peltonen L, Krahe R, Udd B. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. <span><span class="ref-journal">Eur J Hum Genet. </span>2011;<span class="ref-vol">19</span>:776–82.</span> [<a href="/pmc/articles/PMC3137497/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3137497</span></a>] [<a href="/pubmed/21364698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21364698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.tapscott.2001.816">Tapscott SJ, Thornton CA. Biomedicine. Reconstructing myotonic dystrophy. <span><span class="ref-journal">Science. </span>2001;<span class="ref-vol">293</span>:816–7.</span> [<a href="/pubmed/11486078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11486078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.thornton.1999.25">Thornton C. The myotonic dystrophies. <span><span class="ref-journal">Semin Neurol. </span>1999;<span class="ref-vol">19</span>:25–33.</span> [<a href="/pubmed/10711986" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10711986</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.tieleman.2011.1820">Tieleman AA, Jenks KM, Kalkman JS, Borm G, van Engelen BG. High disease impact of myotonic dystrophy type 2 on physical and mental functioning. <span><span class="ref-journal">J Neurol. </span>2011;<span class="ref-vol">258</span>:1820–6.</span> [<a href="/pmc/articles/PMC3184219/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3184219</span></a>] [<a href="/pubmed/21461958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21461958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.tieleman.2008.646">Tieleman AA, van Vliet J, Jansen JB, van der Kooi AJ, Borm GF, van Engelen BG. Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. <span><span class="ref-journal">Neuromuscul Disord. </span>2008;<span class="ref-vol">18</span>:646–9.</span> [<a href="/pubmed/18602828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18602828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.udd.2001.561">Udd B, Griggs R. Distal myopathies. <span><span class="ref-journal">Curr Opin Neurol. </span>2001;<span class="ref-vol">14</span>:561–6.</span> [<a href="/pubmed/11562566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11562566</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.udd.2011.443_1">Udd B, Meola G, Krahe R, Wansink DG, Bassez G, Kress W, Schoser B, Moxley R. Myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, Naarden, The Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2011;<span class="ref-vol">21</span>:443–50.</span> [<a href="/pubmed/21543227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21543227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.udd.2003.589">Udd B, Meola G, Krahe R, Thornton C, Ranum L, Day J, Bassez G, Ricker K. Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd Workshop, 14-16 February 2003, Naarden, The Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2003;<span class="ref-vol">13</span>:589–96.</span> [<a href="/pubmed/12921797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12921797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.udd.2006.403">Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, Kress W, Schoser B, Moxley R. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. <span><span class="ref-journal">Neuromuscul Disord. </span>2006;<span class="ref-vol">16</span>:403–13.</span> [<a href="/pubmed/16684600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16684600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.veyckemans.2013.794">Veyckemans F, Scholtes JL. Myotonic dystrophies type 1 and 2: anesthetic care. <span><span class="ref-journal">Paediatr Anaesth. </span>2013;<span class="ref-vol">23</span>:794–803.</span> [<a href="/pubmed/23384336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23384336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.vihola.2003.1854">Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A, Mancinelli E, Rouche A, Hogrel JY, Laforet P, Maisonobe T, Pellissier JF, Krahe R, Eymard B, Udd B. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">60</span>:1854–7.</span> [<a href="/pubmed/12796551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12796551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.von_tell.2002.544">von Tell D, Somer H, Udd B, Edstr&#x000f6;m L, Borg K, Ahlberg G. Welander distal myopathy outside the Swedish population: phenotype and genotype. <span><span class="ref-journal">Neuromuscul Disord. </span>2002;<span class="ref-vol">12</span>:544–7.</span> [<a href="/pubmed/12117477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12117477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.wahbi.2009.468">Wahbi K, Meune C, B&#x000e9;cane HM, Lafor&#x000ea;t P, Bassez G, Lazarus A, Radvanyi-Hoffman H, Eymard B, Duboc D. Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study. <span><span class="ref-journal">Neuromuscul Disord. </span>2009;<span class="ref-vol">19</span>:468–72.</span> [<a href="/pubmed/19481939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19481939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.weihl.2006.189">Weihl CC, Dalal S, Pestronk A, Hanson PI. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:189–99.</span> [<a href="/pubmed/16321991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16321991</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.weingarten.2010.248">Weingarten TN, Hofer RE, Milone M, Sprung J. Anesthesia and myotonic dystrophy type 2: a case series. <span><span class="ref-journal">Can J Anaesth. </span>2010;<span class="ref-vol">57</span>:248–55.</span> [<a href="/pubmed/20077169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20077169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myotonic-d2.REF.win.2012.130">Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM. Increased cancer risks in myotonic dystrophy. <span><span class="ref-journal">Mayo Clin Proc. </span>2012;<span class="ref-vol">87</span>:130–5.</span> [<a href="/pmc/articles/PMC3498332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3498332</span></a>] [<a href="/pubmed/22237010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22237010</span></a>]</div></li></ul></div></div><div id="myotonic-d2.Chapter_Notes"><h2 id="_myotonic-d2_Chapter_Notes_">Chapter Notes</h2><div id="myotonic-d2.Patient_Information"><h3>Patient Information</h3><p>Muscular Dystrophy Association<br />Web: <a href="http://mda.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">mda.org</a></p><p>Myotonic Dystrophy Foundation<br />Web: <a href="http://www.myotonic.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.myotonic.org</a></p></div><div id="myotonic-d2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>3 July 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 April 2007 (jwd) Revision: Allele sizes; to provide information to aid clinicians in interpreting test reports</div></li><li class="half_rhythm"><div>21 September 2006 (me) Review posted to live Web site</div></li><li class="half_rhythm"><div>14 June 2004 (jwd) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1466</span><span class="label">PMID: <a href="/pubmed/20301639" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301639</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/myotonic-d/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/norrie/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1466&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1466/?report=reader">PubReader</a></li><li><a href="/books/NBK1466/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1466" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1466" style="display:none" title="Cite this Page"><div class="bk_tt">Dalton JC, Ranum LPW, Day JW. Myotonic Dystrophy Type 2. 2006 Sep 21 [Updated 2013 Jul 3]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1466/pdf/Bookshelf_NBK1466.pdf">PDF version of this page</a> (505K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#myotonic-d2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#myotonic-d2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#myotonic-d2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#myotonic-d2.Genetically_Related_Allelic" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#myotonic-d2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#myotonic-d2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#myotonic-d2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#myotonic-d2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#myotonic-d2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#myotonic-d2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#myotonic-d2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7555[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CNBP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1469210" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1469210" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1469210" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1469210" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301344" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Myotonic Dystrophy Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Myotonic Dystrophy Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bird TD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12601109" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.</a><span class="source">[Neurology. 2003]</span><div class="brieflinkpop offscreen_noflow">Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurology. 2003 Feb 25; 60(4):657-64. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301609" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bonne G, Leturcq F, Ben Yaou R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301305" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculopharyngeal Muscular Dystrophy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculopharyngeal Muscular Dystrophy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Trollet C, Gidaro T, Klein P, Périé S, Butler-Browne G, Lacau St Guily J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25186227" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Phenotypic variability and molecular genetics in proximal myotonic myopathy.</a><span class="source">[Muscle Nerve. 2015]</span><div class="brieflinkpop offscreen_noflow">Phenotypic variability and molecular genetics in proximal myotonic myopathy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Papadimas GK, Kekou K, Papadopoulos C, Kararizou E, Kanavakis E, Manta P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Muscle Nerve. 2015 May; 51(5):686-91. Epub 2015 Mar 31.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301639" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301639" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04178c75f66d18aa72e3ed">Myotonic Dystrophy Type 2 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Myotonic Dystrophy Type 2 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:14:36-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE8992CFE0410DE10000000003590179&amp;ncbi_session=CE8992CFE04178B1_0857SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1466%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1466&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1466/&amp;ncbi_pagename=Myotonic Dystrophy Type 2 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8992CFE04178B1_0857SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>